DBL CEPHALOTIN SODIUM 1g powder for injection vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

dbl cephalotin sodium 1g powder for injection vial

juno pharmaceuticals pty ltd - cefalotin sodium, quantity: 1.058 g (equivalent: cefalotin, qty 1 g) - injection, powder for - excipient ingredients: sodium bicarbonate - indications: cephalothin sodium for injection is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. culture and susceptibility studies should be performed. however, therapy may be instituted before results of susceptibility studies are obtained (see pharmacology: microbiology). respiratory tract: infections caused by s. pneumoniae, staphylococci (penicillinase and nonpenicillinase producing), group a beta-haemolytic streptococci, klebsiella, and h. influenzae. skin and soft tissue: infections, including peritonitis, caused by staphylococci (penicillinase and nonpenicillinase producing), group a beta-haemolytic streptococci, e.coli, pr. mirabilis and klebsiella. genitourinary tract: infections caused by e. coli, pr. mirabilis and klebsiella. septicaemia, including endocarditis: infections caused by s. pneumoniae, staphylococci (penicillinase and nonpenicillinase producing), group a beta-haemolytic streptococci, s. viridans, e. coli, pr. mirabilis and klebsiella. bone and joint: infection caused by staphylococci (penicillinase and non-penicillinase producing). prophylactically in vaginal hysterectomy, head and neck surgery, insertion of prosthetic heart valves, and prosthetic arthroplasty. cephalothin is not recommended for gastrointestinal procedures or other sites where anaerobic organisms such as bacteriodes tend to prevail. dosage is required pre-, intra-and postoperatively (i.e perioperatively, see dosage and administration). if signs of postoperative infection develop, specimens should be cultured to identify the causative organism so that appropriate therapy can be instituted. note: if the susceptibility tests show that the causative organism is resistant to cephalothin, other appropriate antibiotic therapy should be instituted.

Ledertrexate Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

ledertrexate

wyeth (nz) ltd - methotrexate 2.5 mg/ml;   - solution for injection - 2.5 mg/ml - active: methotrexate 2.5 mg/ml   excipient: sodium chloride sodium hydroxide water for injection

Ledertrexate Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

ledertrexate

wyeth (nz) ltd - methotrexate 25 mg/ml;   - solution for injection - 25 mg/ml - active: methotrexate 25 mg/ml   excipient: sodium chloride sodium hydroxide water for injection

Ledertrexate Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

ledertrexate

wyeth (nz) ltd - methotrexate 2.5mg (as disodium salt);  ;   - tablet - 2.5 mg - active: methotrexate 2.5mg (as disodium salt)     excipient: lactose monohydrate magnesium stearate sodium hydroxide starch

Ledertrexate 2,5 mg tabl. Бельгія - англійська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ledertrexate 2,5 mg tabl.

pfizer sa-nv - methotrexate disodium 2,74 mg - eq. methotrexate 2,5 mg - tablet - 2,5 mg - methotrexate 2.5 mg - methotrexate; l04ax03 methotrexate

Ledertrexate 5 mg/2 ml inj. sol. i.m./i.v./i.ventricul./i.arter./i.thec. vial Бельгія - англійська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ledertrexate 5 mg/2 ml inj. sol. i.m./i.v./i.ventricul./i.arter./i.thec. vial

pfizer sa-nv - methotrexate disodium 5,48 mg/2 ml - eq. methotrexate 5 mg/2 ml - solution for injection - 5 mg/2 ml - methotrexate 5 mg - methotrexate; l04ax03 methotrexate

Ledertrexate 7,5 mg/ml inj. sol. i.v./i.m./i.arter./i.thec./i.ventricul./s.c. pre-filled syr. Бельгія - англійська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ledertrexate 7,5 mg/ml inj. sol. i.v./i.m./i.arter./i.thec./i.ventricul./s.c. pre-filled syr.

pfizer sa-nv - methotrexate sodium 8,23 mg/ml - eq. methotrexate 7,5 mg/ml - solution for injection - 7,5 mg/ml - methotrexate sodium 8.23 mg/ml - methotrexate; l04ax03 methotrexate

Ledertrexate 15 mg/2 ml inj. sol. i.thec./s.c./i.arter./i.ventricul./i.v./i.m. pre-filled syr. Бельгія - англійська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ledertrexate 15 mg/2 ml inj. sol. i.thec./s.c./i.arter./i.ventricul./i.v./i.m. pre-filled syr.

pfizer sa-nv - methotrexate sodium 8,23 mg/ml - eq. methotrexate 7,5 mg/ml - solution for injection - 7,5 mg/ml - methotrexate sodium 8.23 mg/ml - methotrexate; l04ax03 methotrexate

Ledertrexate Concentrate 5000 mg/50 ml inj. sol. (conc.) i.thec./i.arter./i.ventricul./i.v./i.m. vial Бельгія - англійська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ledertrexate concentrate 5000 mg/50 ml inj. sol. (conc.) i.thec./i.arter./i.ventricul./i.v./i.m. vial

pfizer sa-nv - methotrexate disodium 1096,8 mg/10 ml - eq. methotrexate 1000 mg/10 ml - concentrate for solution for injection - 100 mg/ml - methotrexate 100 mg - methotrexate; l04ax03 methotrexate

Ledertrexate Concentrate 1000 mg/10 ml inj. sol. (conc.) i.thec./i.arter./i.ventricul./i.v./i.m. vial Бельгія - англійська - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ledertrexate concentrate 1000 mg/10 ml inj. sol. (conc.) i.thec./i.arter./i.ventricul./i.v./i.m. vial

pfizer sa-nv - methotrexate disodium 1096,8 mg/10 ml - eq. methotrexate 1000 mg/10 ml - concentrate for solution for injection - 100 mg/ml - methotrexate 100 mg/ml - methotrexate; l04ax03 methotrexate